PharmaShots | Incisive News in 3 Shots

Subscribe Now

NASH

Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH

Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH

July 14, 2021

Boehringer Ingelheim to Develop Dicerna's GalXC RNAi Candidate for NASH

Boehringer Ingelheim to Develop Dicerna's GalXC RNAi Candidate for NASH

May 25, 2021

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NASH

Gilead Expands its Collaboration with Novo Nordisk to Evaluate Triple Combination Regimen for Compensated Cirrhosis (F4) due to NA...

March 19, 2021

Inventiva's Lanifibranor Receives the US FDA's Breakthrough Designation for the Treatment of NASH

Inventiva's Lanifibranor Receives the US FDA's Breakthrough Designation for the Treatment of NASH

October 12, 2020

Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

Zydus' Saroglitazar Receives DCGI's Approval as the World's First Therapy for Non-Cirrhotic NASH in India

March 6, 2020

Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

October 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us